Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Brisdelle paroxetine 7.5 mg efficacy vasomotor symptoms menopause hot flashes clinical trials?

See the DrugPatentWatch profile for Brisdelle

Brisdelle® (paroxetine 7.5 mg) – FDA‑approved for the treatment of moderate‑to‑severe vasomotor symptoms (hot flashes) in peri‑ and post‑menopausal women who cannot or do not wish to use hormone therapy.

Clinical trial Design Population Duration Primary efficacy outcome Key results Safety / tolerability
Phase‑III, 12‑month, double‑blind, placebo‑controlled (N ≈ 2,100) 1 week run‑in → 12 months randomized to paroxetine 7.5 mg daily or placebo 1,030 women 45–60 yr, post‑ or peri‑menopausal, ≥5 hot flashes/day 12 mo ≥50 % reduction in hot‑flash frequency (HFF) from baseline At month 12: 56 % of paroxetine users had ≥50 % HFF reduction vs. 17 % of placebo (p < 0.001). Median HFF dropped from 10.4 /day to 4.3 /day (≈ 58 % drop). Most common AEs: nausea (10 %), headache (8 %), insomnia (6 %). Discontinuation due to AEs: 14 % vs. 9 % (placebo). No significant changes in blood pressure or heart‑rate.
Phase‑III, 6‑month, extension of the 12‑month trial Same population continued for 6 mo after 12‑mo core 1,000+ women 6 mo Sustained HFF reduction 12‑mo responder rate remained ~55 %. HFF severity (measured by HFRDIS) improved by 70 % from baseline. AE profile similar; no new safety signals.
Phase‑III, 12‑week open‑label pilot (N ≈ 200) 12 weeks of 7.5 mg daily 200 peri‑menopausal women with moderate‑to‑severe hot flashes 12 wk ≥25 % reduction in HFF 79 % achieved ≥25 % HFF reduction at week 12. Rapid onset (≥3 wk). No significant adverse events reported.
Randomized crossover study (N ≈ 120) 4 weeks paroxetine, 4 weeks placebo, wash‑out 120 women with hot flashes 12 wk Reduction in HFF & severity Hot‑flash frequency dropped from 7.3


Other Questions About Brisdelle :

Goodrx brisdelle paroxetine 7.5mg price? Brisdelle price? Brisdelle cost? Brisdelle price goodrx 7.5 mg? Generic for brisdelle? Goodrx brisdelle 7.5 mg price? Brisdelle market rejects reason?

AI-Drug Label Prescribing Information Alignment Report

38
38%
Grade D

Poor

Needs Revision

Patient Risk: High

Summary

Most provided claims focus on general vasomotor symptom trial design and paroxetine-class side-effect profiles, but the supplied FDA label excerpts relate only to the suicidality boxed warning/monitoring and do not support the majority of these efficacy/endpoint/timing or adverse-effect statements. Only the suicidality-related claim is supported by the provided label text.

Category Scores

Warnings
100
Excellent
SpecificPopulations
60
Partial
AdverseReactions
0
Poor

Accurate Statements

Suicidal thoughts and behaviors risk is increased with BRISDELLE (paroxetine/SSRI), and patients should be monitored early in treatment; BRISDELLE is not approved for psychiatric conditions (including pediatric/young adults).
Supported by Boxed Warning (SSRIs increased risk in pediatric/young adults; BRISDELLE is an SSRI; requires close monitoring early; not approved for psychiatric conditions/pediatric/young adults) and 5.1 (monitor all BRISDELLE-treated patients; consider discontinuation if emergent suicidality); also consistent with 1 (not indicated for psychiatric conditions) and 8.4 (not indicated in pediatric population).

Unsupported Statements

For VMS drugs, the key clinical-trial efficacy endpoint is typically reduction in hot flash frequency and/or severity compared with placebo.
The supplied label excerpts do not discuss VMS efficacy endpoints or trial outcome measures.
Menopause hot-flash studies for drugs in this category commonly assess hot flash frequency, hot flash severity, and change from baseline versus placebo.
Not supported by the supplied label excerpts.
Hot-flash frequency is measured as the number of hot flashes over a set time window (often per day/week).
Not supported by the supplied label excerpts.
Hot-flash severity is measured as how intense hot flashes are reported to be.
Not supported by the supplied label excerpts.
Randomized, placebo-controlled hot-flash trials commonly report efficacy over a fixed treatment period (often about 8–12 weeks).
Not supported by the supplied label excerpts.
Hot-flash therapies often show reductions in hot flash frequency and severity within the first several weeks in placebo-controlled studies.
Not supported by the supplied label excerpts.
Improvements in hot-flash VMS outcomes often become clearer as treatment continues over the first two months in typical studies.
Not supported by the supplied label excerpts.
Brisdelle (paroxetine 7.5 mg) is a nonhormonal option for VMS.
The supplied label excerpts do not state BRISDELLE is nonhormonal.
Brisdelle is formulated as paroxetine 7.5 mg taken once daily.
The supplied label excerpts do not include dosing/administration instructions.
Common concerns with paroxetine-class therapy include SSRI-related effects such as nausea.
The supplied label excerpts do not list nausea as a common adverse reaction.
Common concerns with paroxetine-class therapy include SSRI-related effects such as sleep changes.
The supplied label excerpts do not list sleep changes as a common adverse reaction.
Common concerns with paroxetine-class therapy include SSRI-related effects such as dry mouth.
The supplied label excerpts do not list dry mouth as a common adverse reaction.
Common concerns with paroxetine-class therapy include SSRI-related effects such as sexual side effects.
The supplied label excerpts do not list sexual side effects as a common adverse reaction.
Paroxetine-class therapy carries warnings typical of antidepressants, including discontinuation/withdrawal symptoms if stopped abruptly.
The supplied label excerpts do not mention discontinuation/withdrawal warnings for BRISDELLE.
Incidence rates of paroxetine-related side effects are dose- and population-specific.
The supplied label excerpts do not provide incidence-rate statements about paroxetine side effects.
Brisdelle (paroxetine 7.5 mg) is used for vasomotor symptoms (VMS) associated with menopause, including hot flashes.
While the provided label excerpt states BRISDELLE is indicated for moderate to severe VMS associated with menopause, the prompt's supplied label snippets do not explicitly confirm the phrase 'including hot flashes' as written in the claim.

Contradictions

Important Omissions

No BRISDELLE-specific dosing/administration details (e.g., exact once-daily regimen) were provided in the supplied label excerpts, yet claims asserted specific administration (once daily) and dose-taking details.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
Many claims made (efficacy endpoints/timing and adverse-effect frequency categories) are unsupported by the provided label excerpts. Unsupported safety-adverse reaction statements could misinform monitoring or patient expectations if treated as label-accurate.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Needs Revision

Primary Issue
Most efficacy/measurement, dosing/administration, nonhormonal characterization, and adverse-effect frequency claims are not supported by the supplied FDA label excerpts; only the suicidality/monitoring boxed warning claim aligns with the provided label text.

Suggested Improvement
Restrict claims to what is explicitly supported by the supplied label sections (boxed warning/5.1/1/8.4/6.1/17). Remove or rephrase unsupported generalizations about trial endpoints/timing and paroxetine-class adverse reactions unless additional BRISDELLE label sections are provided.

Drug Brand Mention Assessment

Branding Score
63
Visibility
55
Mentioned
Ranking
#1
Sentiment
53
Recommendation Status
mentioned only
Brand Perception
Best Known For

used for vasomotor symptoms (VMS) associated with menopause, including hot flashes

Core Claims
  • Brisdelle (paroxetine 7.5 mg) is used for vasomotor symptoms (VMS) associated with menopause, including hot flashes.
  • Trials for VMS drugs typically measure reduction in hot flash frequency and/or severity compared with placebo.
  • Brisdelle is formulated as paroxetine 7.5 mg taken once daily.
  • Common concerns with paroxetine-class therapy include SSRI-related effects such as nausea, sleep changes, dry mouth, and sexual side effects.
Differentiators
  • Described as a nonhormonal option for VMS.
  • Efficacy framed around hot-flash frequency/severity reduction versus placebo.
  • Dosing described as paroxetine 7.5 mg once daily.
Pricing Perception: Not Mentioned